Metronomic therapy

Digital Health Start-up, Metronomic, Working on improving outcomes in pregnancy care through their platform Materno™

Retrieved on: 
Tuesday, May 30, 2023
Pressure, Insurance, Pregnancy, Femtech, Gestational diabetes, OBGYN, Woman, MBA, Mother, Metronomic therapy, Patient, Risk, Pre-eclampsia, Mortality, Death, Dietary supplement, Nursing, Juan Materno Vásquez de León

Materno™ is a digital platform that gives mothers access to OBGYNs, human care managers, remote monitoring, telehealth and other insightful features that allow them to take charge of their pregnancy.

Key Points: 
  • Materno™ is a digital platform that gives mothers access to OBGYNs, human care managers, remote monitoring, telehealth and other insightful features that allow them to take charge of their pregnancy.
  • Firstly, they provide customized and personalized care plans that align with clinical evidence and are supported by AI-powered predictions.
  • This increases the likelihood of complications being identified earlier to safeguard pregnant mothers and their babies, from common health issues typically associated with pregnancy.
  • Thirdly, the platform helps eliminate preventable complications costs and reduces the overall costs of care for pregnant mothers and for insurance companies.

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, June 22, 2021
Cancer, Clinical medicine, Orphan drugs, Prostate cancer, Breakthrough therapy, Histopathology, Enzalutamide, Pembrolizumab, Protein-bound paclitaxel, Pancreatic cancer, Metronomic therapy, Atezolizumab

Metastatic pancreatic cancer is a dire disease and patients who have relapsed following multiple lines of therapy have no effective treatment options.

Key Points: 
  • Metastatic pancreatic cancer is a dire disease and patients who have relapsed following multiple lines of therapy have no effective treatment options.
  • Our trials of relacorilant plus pembrolizumab in patients with adrenal cancer and of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer continue to enroll.
  • RELIANT is a single-arm, multicenter, open-label, Phase 3 trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer, with a planned enrollment of 80 patients and a planned interim analysis of outcomes in the first 40 patients.
  • In this press release, forward-looking statements, include those concerning the clinical attributes of relacorilant and its potential benefits in patients with pancreatic cancer patients and metastatic ovarian cancer, as well as the progress, timing and results of our trials of relacorilant in ovarian cancer, adrenal cancer and of exicorilant in castration-resistant prostate cancer.

aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting

Retrieved on: 
Friday, April 9, 2021
Clinical medicine, Cancer treatments, Medicine, Orphan drugs, Lung cancer, Antineoplastic drugs, Bevacizumab, Chemotherapy, Non-small-cell lung carcinoma, Breast cancer, Treatment of lung cancer, Metronomic therapy

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer.

Key Points: 
  • Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer.
  • ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast cancer model.
  • In animal models of non-small cell lung cancer, ATYR2810 administered therapeutically as a single agent significantly inhibited tumor growth.
  • We look forward to continuing IND-enabling activities for ATYR2810 to support advancement to clinical trials in cancer in the future.